Summary

Based on the data provided and the conditions described, here are diseases starting with the letter S that are currently research ends (experimental) or in clinical trials, or are currently predominantly suppressed/reactive in real patients (not currently studyable):

1. Sarcoidosis: While recently approved for investigational initiation in adult adults (replaced by other drugs), it is not currently a direct target of clinical research.
2. Sarcoidosis of the lung: It has been studied in the laboratory in vitro but is not a real disease that is being treated in a clinical or experimental setting (it is more of a drug for the disease).
3. Sarcoidosis of the skin: Has not been demonstrated in the laboratory and is not a focus of clinical research.
4. Sarcoidosis of the heart: Not currently an experimentally treatable condition (this is a goal in the future).
5. Complex tuberous sclerosis: It is the most frequent disease in the literature but has not been found in the laboratory.
6. Aldosteromia Syndrome: It is not a real disease.
7. Antibody Syndrome (SAS): It is not a real disease.
8. Carcinoma syndrome (metastatic carcinoma): Has not been proven in the laboratory.
9. Rokitansky-Aschoff Syndrome (SAO): It was found in the laboratory, but it is not a real disease.
10. Malignant tumor of the central nervous system (TNS): Experiments in progress.
11. Malignatic tumor of liver cirrhosis (TMEC): It was found in the laboratory, but it is not a real disease.
12. Pancreatic Cirrhosis Malignant Tumor (TPMC): It was found in the laboratory, but it is not a real disease.
13. Cirrhosis of the intestine malignant tumor (TMEI): It was found in the laboratory, but it is not a real disease.
14. Renal cirrhosis malignancy (TMR): Ongoing experiments.
15. Cirrhosis of the lung malignant tumor (TMRP): Experiments in progress.
16. Genital cirrhosis malignant tumor (TMRG): Experiments in progress.
17. Cirrhosis of the skin malignant tumor (TMPR): Experiments in progress.
18. Thyroid cirrhosis malignant tumor (TMPR): Ongoing experiments.
19. Cirrhosis of the liver malignant tumor (TMRF): Experiments in progress.
20. Cirrhosis of the pancreas malignant tumor (TMRP): Experiments in progress.
21. Cirrhosis of the lung malignant tumor (TMRP): Experiments in progress.
22. Cirrhosis malignancy of the gastrointestinal tract (TMRGI): Ongoing experiments.

In summary, most diseases that start with S have not currently been found in the laboratory (it is important to know that the experimental initiation of some of these requires years of research before they can be applied in real patients), but the main ones that are currently being investigated in a clinical setting or are under study include:

* Sarcoidosis
* Antibody Syndrome (SAS)
* Cirrhosis malignancy (TMEC/TMRC/TPMC/TMEI/TMRF/TMRP/TMRGI)
* Malignant tumor of the central nervous system (TNS)
* Cirrhosis of the lung malignant tumor (TMRP)
* Cirrhosis of the intestine malignant tumor (TMEI)
* Cirrhosis of the skin malignant tumor (TMPR)
* Thyroid cirrhosis malignant tumor (TMPR)
* Genital cirrhosis malignant tumor (TMRG)
* Cirrhosis of the heart malignant tumor (TMEC)
* Cirrhosis of the pancreas malignant tumor (TMRP)
* Cirrhosis of the liver malignant tumor (TMRF)
* Renal cirrhosis malignant tumor (TMR)
* Cirrhosis of the lung malignant tumor (TMRP)
* Intestinal cirrhosis malignant tumor (TMEI)
* Skin cirrhosis malignant tumor (TMPR)
* Sarcoidosis of the heart
* Malignant tumor of the central nervous system (TNS)

Title

European Clinical Trials Information Network | We connect patients with clinical trials

Description

Discover Studi-Clinici.it – a patient-centered platform that connects you to clinical trials across Europe. Find reliable, localized information on studies for your disease. Empower patients, research centers and sponsors. Explore now!

Keywords

sarcoma, deficit, adenocarcinoma, carcinoma, base, colon, glioma, europa, anti, edema, anemia, sodium

NS Lookup

A 104.26.15.248, A 172.67.73.108, A 104.26.14.248

Dates

Created 2026-04-13

Updated 2026-04-15

Summarized 2026-04-16